Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MRC Delivering on the Life Sciences Strategy, One Year On

Published: Tuesday, December 11, 2012
Last Updated: Tuesday, December 11, 2012
Bookmark and Share
The Medical Research Council has made significant progress in implementing the measures outlined in last year’s Strategy for UK Life Sciences, according to a progress update published by the Government.

The Strategy for UK Life Sciences: One Year On report summarises the progress made in the 12 months since the strategy was launched and also announces a number of new measures, including a £20 million investment in regenerative medicine as part of the £600m science capital funding unveiled in the Government’s Autumn Statement earlier this month.

Among the successes has been the establishment of the MRC/Technology Strategy Board Biomedical Catalyst, which so far has committed £49m to 64 projects. This will leverage at least £25m of private sector funding. The Catalyst is designed to support academics and businesses to explore the market potential of their early-stage scientific ideas, and accelerate the development of innovative solutions to healthcare challenges.

The update also highlights recent MRC funding of £7m for 15 research projects awarded through its groundbreaking ‘compound collaboration’ with AstraZeneca. This was the first scheme of its kind, and gave scientists access to 22 AstraZeneca compounds which are now being used by academics to study a broad range of conditions from diseases like Alzheimer’s, cancer and lung disease through to rarer conditions such as motor neurone disease and muscular dystrophies. In November 2012, this ground-breaking initiative won ‘Best Partnership Alliance’ at the annual SCRIP Awards event in London.

Other initiatives by the MRC included in the One Year On report are:

•    An investment of £60m over three years through the MRC Experimental Medicine Challenge Grants. A large number of outline applications have been received and 30 full-stage applications are now being assessed through rigorous international peer review.
•    £9.6m provided for the expansion of UK Biobank. This will include 8,000 brain scans, and one project aims to help scientists discover why some people develop dementia and others do not.
•    An investment of £10.6m in three large-scale collaborative awards under the MRC’s Stratified Medicine Initiative. These stratified medicine consortia will tackle diseases which have a huge impact on patient’s lives – rheumatoid arthritis, hepatitis C and a rare condition called Gaucher disease. This builds on £11.5 investment in pilot consortia focusing on chronic obstructive pulmonary disease, rheumatoid arthritis and diabetes (the MASTERMIND consortia).
•    A joint commitment by the MRC, the Engineering and Physical Sciences Research Council and the Biotechnology and Biological Sciences Research Council to jointly invest £25m over five years to maximise the potential of the Cell Therapy Catapult.
•    A consortium of 10 UK government and charity research funders led by the MRC has awarded £19m to four e-health research Centres of Excellence based in London, Manchester, Dundee and Swansea.
•    The MRC-NIHR Phenome Centre, which will analyse thousands of samples of blood, urine and tissue to discover how our genes interact with our environment to cause and affect the course of disease, will open at Imperial College London in 2013.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MRC Technology, Alzheimer’s Association Collaborate
MRC Technology (MRCT), an independent medical research charity based in London, and the Alzheimer’s Association in Chicago have entered into an agreement to review and monitor the Association’s grant-funded research portfolio.
Thursday, January 21, 2016
Study Identifies New Way to Kill the Malaria Parasite
Scientists have discovered new ways in which the malaria parasite survives in the blood stream of its victims, a discovery that could pave the way to new treatments for the disease.
Tuesday, July 07, 2015
AstraZeneca, MRC Collaboration to Create New Centre for Early Drug Discovery
The Companies today announced the groundbreaking collaboration aimed at better understanding the mechanisms of human disease. The collaboration will see the creation of a joint research facility at AstraZeneca’s new R&D centre in Cambridge in the UK.
Monday, March 31, 2014
Scientists Edge Closer Towards First Pancreatitis Treatment
Scientists have provided proof of principle for a drug-based treatment of acute pancreatitis – a disease for which currently there is no treatment.
Friday, July 26, 2013
MRC and AstraZeneca Scoop Prestigious SCRIP Award
The innovative collaboration between the Medical Research Council and AstraZeneca has won the ‘Best Partnership Alliance’ award at the annual SCRIP Awards.
Tuesday, December 04, 2012
A Phenomenal Legacy for London 2012
The Phenome Centre will use the cutting edge facilities developed for London 2012 to help develop better and more targeted treatment for patients.
Wednesday, August 01, 2012
Scientific News
Drugs that May Combat Deadly Antibiotic-Resistant Bacteria Uncovered
Study identifies 79 compounds that inhibit carbapenem-resistant Enterobacteriaceae (CRE).
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!